PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17654759-0	2007	Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.	LY 353381	128-138	estrogen receptor 1	Homo sapiens	74-91
25378950-3	2014	Other selective estrogen receptor modulators (SERMs), such as raloxifene, arzoxifene, and lasofoxifene, have been shown to reduce the incidence of breast cancer by 50%-80%.	LY 353381	74-84	estrogen receptor 1	Homo sapiens	16-33
22484799-11	2012	These findings demonstrate that in this study arzoxifene reduced the risk of ER-positive breast cancer in this population of postmenopausal women with low bone mass or osteoporosis, an effect similar to that seen with other SERMs.	LY 353381	46-56	estrogen receptor 1	Homo sapiens	77-79
21993078-1	2012	OBJECTIVE: The aim of this study was to report the gynecologic safety findings from the Generations trial, a phase 3 study of the selective estrogen receptor modulator (SERM), arzoxifene.	LY 353381	176-186	estrogen receptor 1	Homo sapiens	140-157
19798460-7	2010	RESULTS: All arzoxifene doses significantly reduced osteocalcin (primary endpoint), type 1 collagen C-telopeptide, bone specific alkaline phosphatase, and procollagen type I amino-terminal propeptide versus placebo, and increased lumbar spine BMD.	LY 353381	13-23	bone gamma-carboxyglutamate protein	Homo sapiens	52-63
19477949-0	2009	Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1.	LY 353381	27-37	cyclin D1	Homo sapiens	71-80
19477949-3	2009	Arzoxifene is an effective growth inhibitor of ERalpha-positive breast cancer cells, including tamoxifen-resistant tumors.	LY 353381	0-10	estrogen receptor 1	Homo sapiens	47-54
19477949-4	2009	In this study, we show that overexpression of a regular component of the ERalpha transcription factor complex, cyclin D1, which occurs in approximately 40% of breast cancer patients, renders cells resistant to the new promising antiestrogen, arzoxifene.	LY 353381	242-252	estrogen receptor 1	Homo sapiens	73-80
19477949-4	2009	In this study, we show that overexpression of a regular component of the ERalpha transcription factor complex, cyclin D1, which occurs in approximately 40% of breast cancer patients, renders cells resistant to the new promising antiestrogen, arzoxifene.	LY 353381	242-252	cyclin D1	Homo sapiens	111-120
19477949-5	2009	Overexpression of cyclin D1 alters the conformation of ERalpha in the presence of arzoxifene.	LY 353381	82-92	cyclin D1	Homo sapiens	18-27
19477949-5	2009	Overexpression of cyclin D1 alters the conformation of ERalpha in the presence of arzoxifene.	LY 353381	82-92	estrogen receptor 1	Homo sapiens	55-62
19477949-6	2009	In this altered conformation, ERalpha still recruits RNA polymerase II to an estrogen response element-containing promoter, inducing transcription of an ERalpha-dependent reporter gene and of endogenous pS2, and promoting arzoxifene-stimulated growth of MCF-7 cells.	LY 353381	222-232	estrogen receptor 1	Homo sapiens	30-37
19477949-7	2009	Arzoxifene is then converted from an ERalpha antagonist into an agonist.	LY 353381	0-10	estrogen receptor 1	Homo sapiens	37-44
19477949-8	2009	This can be explained by a stabilization of the ERalpha/steroid receptor coactivator-1 complex in the presence of arzoxifene, only when cyclin D1 is overexpressed.	LY 353381	114-124	estrogen receptor 1	Homo sapiens	48-55
19477949-8	2009	This can be explained by a stabilization of the ERalpha/steroid receptor coactivator-1 complex in the presence of arzoxifene, only when cyclin D1 is overexpressed.	LY 353381	114-124	cyclin D1	Homo sapiens	136-145
17876041-1	2007	The benzothiophene selective estrogen receptor modulators (SERM) raloxifene and arzoxifene are in clinical use and clinical trials for chemoprevention of breast cancer and other indications.	LY 353381	80-90	estrogen receptor 1	Homo sapiens	29-46
17876041-6	2007	Livers from female, juvenile rats treated for 3 days with estradiol and/or with the benzothiophene SERMs arzoxifene, DMA, and F-DMA showed substantial induction of NQO1 by the benzothiophene SERMs.	LY 353381	105-115	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	164-168
17020999-0	2006	The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.	LY 353381	95-105	estrogen receptor 1 (alpha)	Mus musculus	59-76
17020999-0	2006	The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.	LY 353381	95-105	estrogen receptor 1 (alpha)	Mus musculus	188-205
12927029-3	2003	Furthermore, new selective estrogen-receptor modulators such as arzoxifene, currently under clinical development, offer the possibility of selecting one with a more ideal pharmacological profile for treatment and prevention of breast cancer.	LY 353381	64-74	estrogen receptor 1	Homo sapiens	27-44
15720120-0	2005	Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4"-fluoro substitution prevents quinoid formation.	LY 353381	73-83	estrogen receptor 1	Homo sapiens	31-48
15150113-0	2004	The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.	LY 353381	42-52	distal membrane arm assembly component 2 like	Rattus norvegicus	120-131
14559845-1	2003	Arzoxifene (ARZ) is a selective estrogen receptor (ER) modulator with greater bioavailability than raloxifene which is being developed as treatment for breast cancer.	LY 353381	0-10	estrogen receptor 1	Homo sapiens	32-49
14559845-1	2003	Arzoxifene (ARZ) is a selective estrogen receptor (ER) modulator with greater bioavailability than raloxifene which is being developed as treatment for breast cancer.	LY 353381	0-10	estrogen receptor 1	Homo sapiens	51-53
14559845-1	2003	Arzoxifene (ARZ) is a selective estrogen receptor (ER) modulator with greater bioavailability than raloxifene which is being developed as treatment for breast cancer.	LY 353381	12-15	estrogen receptor 1	Homo sapiens	32-49
14559845-1	2003	Arzoxifene (ARZ) is a selective estrogen receptor (ER) modulator with greater bioavailability than raloxifene which is being developed as treatment for breast cancer.	LY 353381	12-15	estrogen receptor 1	Homo sapiens	51-53
14559845-7	2003	ARZ and TAM resulted in a significant (P < 0.001) increase in ER expression and reduction in progesterone receptor expression, whereas changes in cyclin D1 score were inversely related to p27(kip1) score.	LY 353381	0-3	progesterone receptor	Homo sapiens	96-117
14559845-7	2003	ARZ and TAM resulted in a significant (P < 0.001) increase in ER expression and reduction in progesterone receptor expression, whereas changes in cyclin D1 score were inversely related to p27(kip1) score.	LY 353381	0-3	interferon alpha inducible protein 27	Homo sapiens	191-194
14559845-7	2003	ARZ and TAM resulted in a significant (P < 0.001) increase in ER expression and reduction in progesterone receptor expression, whereas changes in cyclin D1 score were inversely related to p27(kip1) score.	LY 353381	0-3	cyclin dependent kinase inhibitor 1B	Homo sapiens	195-199
15149724-4	2004	Northern analysis revealed that arzoxifene exerts a statistically significant inhibition of pS2 and progesterone receptor B mRNA expression.	LY 353381	32-42	trefoil factor 1	Homo sapiens	92-95
14559845-0	2003	Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.	LY 353381	56-66	estrogen receptor 1	Homo sapiens	28-45
14559845-0	2003	Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.	LY 353381	68-76	estrogen receptor 1	Homo sapiens	28-45
14555537-8	2003	CONCLUSIONS: Arzoxifene and 4OHT can inhibit specifically the repopulation of ER+ breast cancer cells between courses of chemotherapy.	LY 353381	13-23	estrogen receptor 1	Homo sapiens	78-80
11283133-0	2001	Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.	LY 353381	75-83	estrogen receptor 1	Homo sapiens	46-63
11911997-9	2002	There was a significant increase in TPH total signal (positive pixelsxOD) with E, raloxifene and arzoxifene, respectively.	LY 353381	97-107	tryptophan hydroxylase 1	Macaca mulatta	36-39
11911997-13	2002	In conclusion, the selective estrogen receptor modulators, raloxifene and arzoxifene, act in a manner similar to natural E on TPH and SERT mRNA expression in serotonin neurons.	LY 353381	74-84	tryptophan hydroxylase 1	Macaca mulatta	126-129
11911997-13	2002	In conclusion, the selective estrogen receptor modulators, raloxifene and arzoxifene, act in a manner similar to natural E on TPH and SERT mRNA expression in serotonin neurons.	LY 353381	74-84	solute carrier family 6 member 4	Macaca mulatta	134-138
11911997-14	2002	This suggests that raloxifene and arzoxifene are agonists at ER beta in the context of the serotonin neuron.	LY 353381	34-44	estrogen receptor 2	Macaca mulatta	61-68
11283133-1	2001	PURPOSE: We conducted this phase I trial to determine the safety and toxicity profile of LY353381.HCl-a novel, potent, third-generation selective estrogen receptor modulator (SERM)-because this benzothiophene derivative demonstrated an SERM profile in preclinical studies.	LY 353381	89-97	estrogen receptor 1	Homo sapiens	146-163
10965916-5	2000	The dose of chemical necessary to activate IGF-I signaling varied, with the order of potency: E2 = diethylstilbestrol > LY353381 > 4-hydroxytamoxifen > genistein > HPTE > bisphenol A.	LY 353381	123-131	insulin-like growth factor 1	Mus musculus	43-48
9794476-13	1998	Additionally, when PTH was discontinued at 45 days, LY353381 x HCl prevented the rapid loss of bone observed in controls.	LY 353381	52-60	parathyroid hormone	Equus caballus	19-22